Relationship Between Tadalafil Exposure with Reduced Rates of MACE and Mortality in Men with ED
The following is a summary of “Association of tadalafil exposure with lower rates of major adverse cardiovascular events and mortality in a general population of men with erectile dysfunction,” published in the February 2024 issue of Cardiology by Kloner et al. Tadalafil, a phosphodiesterase-5 inhibitor (PDE-5i), is prescribed for the treatment of erectile dysfunction (ED)